Biotin‐new indocyanine green conjugate: Synthesis, in vitro photocytotoxicity and in vivo biodistribution

Shengping Liu,Fang Ding,Wei Xu,Liangrui Miu,Yuxiang Tang,Defeng Xu,Tianyu Zhu,Hang Hu
DOI: https://doi.org/10.1111/cbdd.14495
2024-03-07
Chemical Biology & Drug Design
Abstract:Biotin‐SS‐IR820 displays significantly enhanced cellular uptake amount, enhanced in vitro photocytotoxicity and enhanced in vivo tumor accumulation as compared to IR820, showing great potential for targeted theranostics of biotin receptor overexpressed tumors. New indocyanine green (ICG) (IR820) is one of the ICG derivatives and attracts increasing attention for cancer management. However, the unsatisfactory tumor targeting ability of IR820 significantly limits its applications for cancer theranostics. Biotin receptor is overexpressed on the membrane of various tumor cells and biotin modified nanocarriers have been reported to enhance the tumor targeting ability on several tumor types. In this work, biotin‐new ICG conjugate (Biotin‐SS‐IR820) was prepared for tumor‐targeted IR820 delivery. Biotin and IR820 were coupled through cystamine. The synthesized Biotin‐SS‐IR820 was characterized by 1H NMR, FT‐IR and HRMS. The in vitro singlet oxygen generation study shows that Biotin‐SS‐IR820 exhibits similar singlet oxygen generation as compared to IR820 upon 660 nm laser irradiation (0.8 W/cm2). The cellular uptake study shows that Biotin‐SS‐IR820 shows enhanced cellular uptake amount as compared to IR820 on 4T1 cells. As a result, Biotin‐SS‐IR820 displays enhanced in vitro photodynamic therapeutic effect against 4T1 cells as compared to IR820. In in vivo biodistribution study, Biotin‐SS‐IR820 shows enhanced tumor accumulation as compared to IR820. Biotin‐SS‐IR820 developed in this work shows promising prospects for targeted delivery of IR820 to biotin receptor overexpressed tumors.
biochemistry & molecular biology,chemistry, medicinal
What problem does this paper attempt to address?